70
Participants
Start Date
October 10, 2023
Primary Completion Date
January 31, 2025
Study Completion Date
March 31, 2025
Ompenaclid
Ompenaclid (RGX-202-01)
Placebo
Placebo
Bevacizumab
Bevacizumab
FOLFIRI regimen
FOLFIRI regimen (irinotecan 180 mg/m2 over 90 minutes concurrently with folinic acid 400 mg/m2 over 2 hours, and then 5-FU 2400 mg/m2 over 46 hours on Days 1 and 15 of each 28-day cycle)
UZ Brussel, Brussels
Universite Catholique de Louvain (UCL) - Cliniques Universitaires Saint-Luc, Woluwe-Saint-Lambert
Antwerp University Hospital, Antwerp
Imelda Ziekenhuis, Bonheiden
UZ Leuven, Leuven
CHU de Liège University hospital in Liège, Liège
Grand Hoptial De Charleroi, Charleroi
Institut Paoli-Calmettes, Marseille
Hospital Universitario Reina Sofía, Córdoba
Centre Georges-François Leclerc, Dijon
Hopital Prive des Cotes d'Armor, Plérin
CHU Hôpital Jean Minjoz, Besançon
Hospital Universitario Ramón y Cajal, Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital Puerta de Hierro Majadahonda, Majadahonda
Hospital Puerta de Hierro Majadahonda, Madrid
Hospital Universitario Marqués de Valdecilla, Santander
Hospital Universitario Virgen de Valme, Seville
CHU Nantes -hopital hotel Dieu, Nantes
Institut de Cancerologie de l'Ouest, Saint-Herblain
Hospital Clinico De Valencia, Valencia
Hospital Clinico Universitario De Valencia, Valencia
Groupe Hospitalier Paris Saint Joseph - Oncologie, Paris
Institut Gustave Roussy, Villejuif
Institut Jules Bordet, Anderlecht
Hospital de la Santa Creu i Sant Pau, Barcelona
Hospital del Mar, Barcelona
Hospital Universitari Vall D Hebron, Barcelona
Lead Sponsor
Inspirna, Inc.
INDUSTRY